Here's a story about a small biotech company trying to become a slightly bigger biotech company. Curanex Pharmaceuticals, Inc. (CURX) said on Thursday it's expanding its drug development pipeline. This is the kind of thing biotech companies say when they want investors to know they're not just a one-trick pony, but are building a portfolio of potential treatments.
Right now, Curanex's pipeline has six core indications: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease (NAFLD), and gout. It's a mix of inflammatory and metabolic conditions. The new addition is something different: cancer cachexia.
If you're not familiar, cancer cachexia is a serious, cancer-associated wasting syndrome. It's marked by progressive weight loss, muscle depletion, weakness, and declining physical function. It's a major problem for many cancer patients, affecting their quality of life and their ability to withstand treatment. The CEO, Jun Liu, called it "one of the largest unmet needs in supportive oncology." In other words, there aren't great treatments for it, and a lot of patients suffer. Liu added, "We believe this area represents a meaningful opportunity for focused drug development and an important step in the evolution of Curanex into a broader therapeutics development company." That's corporate-speak for: we're growing up and looking at bigger markets.
And it is a big market. According to Grand View Research data cited by the company, the global cancer cachexia market was about $2.54 billion in 2024 and is projected to grow to $3.90 billion by 2033. That's the kind of number that gets investors' attention.
But Curanex isn't starting from scratch with this new focus. Its lead program, called Phyto-N, is already chugging along. It's currently in preclinical studies, being groomed for a planned Investigational New Drug (IND) submission—but for ulcerative colitis, not cachexia. An IND is the big application you file with the FDA to say, "Hey, we think this drug is safe enough to start testing in humans." Curanex is targeting submission of that first IND in the fourth quarter of 2026.
To get there, they've been busy with the necessary, if unglamorous, work of drug development. Back in February, they completed a pilot-scale batch of Phyto-N that complies with Good Manufacturing Practice (GMP) standards. This batch is meant to support the more rigorous toxicology and pharmacokinetic studies that are required under Good Laboratory Practice (GLP) rules before the IND can be filed.
And on that front, the company had some good news to report. A 28-day repeat-dose study of Phyto-N in rats and dogs showed "no findings of toxicological significance at the maximum feasible dose." In plain English, they gave the animals as much of the drug as they practically could for 28 days, and nothing alarmingly toxic happened. This is a key milestone because it allows the program to advance into the formal GLP toxicology program, which is a major box to check on the path to the clinic.
The company also noted it is evaluating additional development opportunities in other serious diseases that involve inflammation, metabolic dysfunction, and physical decline. So the expansion into cachexia might just be the beginning.
As for the stock, shares of Curanex closed at $0.51 on Wednesday. For a clinical-stage biotech, news like this—pipeline expansion, positive preclinical data, a clear regulatory pathway—is the currency they trade in as they try to convince the market they're on a path to creating value.
